Amedisys (AMED) Tops Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Amedisys (AMED) Could Help Transform Healthcare - Mizuho
March 10, 2016 7:39 AM ESTMizuho analyst, Sheryl Skolnick, thinks Amedisys Inc's (NASDAQ: AMED) turnaround continues to impress as it proceeds on multiple fronts, driving better than expected 4Q15 results, meaningful 2016 improvements and likely strong 2017 growth. Increasing transparency into the progress, costs, timing and returns to the turnaround strategies are making the Street increasingly confident and supported a strong move in the stock. The analyst thinks AMED is strongly positioned not only as a post-acute... More
